0001567619-22-005517.txt : 20220224 0001567619-22-005517.hdr.sgml : 20220224 20220224191212 ACCESSION NUMBER: 0001567619-22-005517 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220223 FILED AS OF DATE: 20220224 DATE AS OF CHANGE: 20220224 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Peyer James CENTRAL INDEX KEY: 0001843594 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39980 FILM NUMBER: 22673622 MAIL ADDRESS: STREET 1: C/O SENSEI BIOTHERAPEUTICS, INC. STREET 2: 1405 RESEARCH BLVD., STE. 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001829802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 620 PROFESSIONAL DRIVE CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: (240) 243-8000 MAIL ADDRESS: STREET 1: 620 PROFESSIONAL DRIVE CITY: GAITHERSBURG STATE: MD ZIP: 20879 4 1 doc1.xml FORM 4 X0306 4 2022-02-23 0 0001829802 Sensei Biotherapeutics, Inc. SNSE 0001843594 Peyer James C/O SENSEI BIOTHERAPEUTICS, INC. 1405 RESEARCH BLVD. SUITE 125 ROCKVILLE MD 20850 1 0 1 0 Common Stock 2022-02-23 4 P 0 2500 3.80 A 5210786 I See Footnote Common Stock 2022-02-24 4 P 0 15000 3.63 A 5225786 I See Footnote These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein. /s/ Erin Hoffert, Attorney-in-Fact 2022-02-24